|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||39.54|
|Dividend & Yield||0.78 (3.04%)|
|1y Target Est||N/A|
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.
Hands on with Casio's latest high-end G-Shock, the MRG-G1000B-1A4 Akazonae.
BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures. Seventure ...